7:33 am Tesaro announces successful achievement of primary and all secondary endpoints in third and final Phase 3 trial of rolapitant; achieved primary endpoint of complete response in the delayed period following initiation of chemotherapy
View todays social media effects on TSRO
View the latest stocks trending across Twitter. Click to view dashboard
See who TESARO is hiring next, click here to view
